2 news items
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
IFRX
21 May 24
is an investigational drug that has not been approved by the FDA for any indication including for the treatment of COVID-19. There is limited information
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
IFRX
8 May 24
blinded for the sponsor and investigators planned upon enrollment of approximately 30 patients (15 per arm). Depending on the results of the interim
- Prev
- 1
- Next